273 related articles for article (PubMed ID: 28705154)
1. Phenotypic and genomic comparison of Mycobacterium aurum and surrogate model species to Mycobacterium tuberculosis: implications for drug discovery.
Namouchi A; Cimino M; Favre-Rochex S; Charles P; Gicquel B
BMC Genomics; 2017 Jul; 18(1):530. PubMed ID: 28705154
[TBL] [Abstract][Full Text] [Related]
2. The draft genome of Mycobacterium aurum, a potential model organism for investigating drugs against Mycobacterium tuberculosis and Mycobacterium leprae.
Phelan J; Maitra A; McNerney R; Nair M; Gupta A; Coll F; Pain A; Bhakta S; Clark TG
Int J Mycobacteriol; 2015 Sep; 4(3):207-16. PubMed ID: 27649868
[TBL] [Abstract][Full Text] [Related]
3. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
4. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
5. Mycobacterium aurum is Unable to Survive Mycobacterium tuberculosis Latency Associated Stress Conditions: Implications as Non-suitable Model Organism.
Sood S; Yadav A; Shrivastava R
Indian J Microbiol; 2016 Jun; 56(2):198-204. PubMed ID: 27570312
[TBL] [Abstract][Full Text] [Related]
6. Recent developments in genomics, bioinformatics and drug discovery to combat emerging drug-resistant tuberculosis.
Swaminathan S; Sundaramurthi JC; Palaniappan AN; Narayanan S
Tuberculosis (Edinb); 2016 Dec; 101():31-40. PubMed ID: 27865394
[TBL] [Abstract][Full Text] [Related]
7. Application of Mycobacterium smegmatis as a surrogate to evaluate drug leads against Mycobacterium tuberculosis.
Lelovic N; Mitachi K; Yang J; Lemieux MR; Ji Y; Kurosu M
J Antibiot (Tokyo); 2020 Nov; 73(11):780-789. PubMed ID: 32472054
[TBL] [Abstract][Full Text] [Related]
8. Use of Mycobacterium smegmatis deficient in ADP-ribosyltransferase as surrogate for Mycobacterium tuberculosis in drug testing and mutation analysis.
Agrawal P; Miryala S; Varshney U
PLoS One; 2015; 10(4):e0122076. PubMed ID: 25874691
[TBL] [Abstract][Full Text] [Related]
9. Whole genome analysis of an MDR Beijing/W strain of Mycobacterium tuberculosis with large genomic deletions associated with resistance to isoniazid.
Zhang Q; Wan B; Zhou A; Ni J; Xu Z; Li S; Tao J; Yao Y
Gene; 2016 May; 582(2):128-36. PubMed ID: 26854371
[TBL] [Abstract][Full Text] [Related]
10. Mycobacterial genomics and structural bioinformatics: opportunities and challenges in drug discovery.
Waman VP; Vedithi SC; Thomas SE; Bannerman BP; Munir A; Skwark MJ; Malhotra S; Blundell TL
Emerg Microbes Infect; 2019; 8(1):109-118. PubMed ID: 30866765
[TBL] [Abstract][Full Text] [Related]
11. targetTB: a target identification pipeline for Mycobacterium tuberculosis through an interactome, reactome and genome-scale structural analysis.
Raman K; Yeturu K; Chandra N
BMC Syst Biol; 2008 Dec; 2():109. PubMed ID: 19099550
[TBL] [Abstract][Full Text] [Related]
12. Potential of Mycobacterium vanbaalenii as a model organism to study drug transporters of Mycobacterium tuberculosis, Mycobacterium marinum and Mycobacterium ulcerans: homology analysis of M. tuberculosis drug transporters among mycobacterial species.
Gupta AK; Katoch VM; Chauhan DS; Lavania M
Infect Genet Evol; 2012 Jun; 12(4):853-6. PubMed ID: 22127144
[TBL] [Abstract][Full Text] [Related]
13. Structural genomics approach to drug discovery for Mycobacterium tuberculosis.
Ioerger TR; Sacchettini JC
Curr Opin Microbiol; 2009 Jun; 12(3):318-25. PubMed ID: 19481971
[TBL] [Abstract][Full Text] [Related]
14. Whole genome sequencing reveals genomic heterogeneity and antibiotic purification in Mycobacterium tuberculosis isolates.
Black PA; de Vos M; Louw GE; van der Merwe RG; Dippenaar A; Streicher EM; Abdallah AM; Sampson SL; Victor TC; Dolby T; Simpson JA; van Helden PD; Warren RM; Pain A
BMC Genomics; 2015 Oct; 16():857. PubMed ID: 26496891
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel loci associated with mycobacterial isoniazid resistance.
Viswanathan G; Yadav S; Raghunand TR
Tuberculosis (Edinb); 2016 Jan; 96():21-6. PubMed ID: 26786650
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the Mycobacterium smegmatis and BCG models for the discovery of Mycobacterium tuberculosis inhibitors.
Altaf M; Miller CH; Bellows DS; O'Toole R
Tuberculosis (Edinb); 2010 Nov; 90(6):333-7. PubMed ID: 20933470
[TBL] [Abstract][Full Text] [Related]
17. An integrated surrogate model for screening of drugs against Mycobacterium tuberculosis.
Gupta A; Bhakta S
J Antimicrob Chemother; 2012 Jun; 67(6):1380-91. PubMed ID: 22398649
[TBL] [Abstract][Full Text] [Related]
18. Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening.
Manjunatha UH; Smith PW
Bioorg Med Chem; 2015 Aug; 23(16):5087-97. PubMed ID: 25577708
[TBL] [Abstract][Full Text] [Related]
19. Insights from the complete genome sequence of Mycobacterium marinum on the evolution of Mycobacterium tuberculosis.
Stinear TP; Seemann T; Harrison PF; Jenkin GA; Davies JK; Johnson PD; Abdellah Z; Arrowsmith C; Chillingworth T; Churcher C; Clarke K; Cronin A; Davis P; Goodhead I; Holroyd N; Jagels K; Lord A; Moule S; Mungall K; Norbertczak H; Quail MA; Rabbinowitsch E; Walker D; White B; Whitehead S; Small PL; Brosch R; Ramakrishnan L; Fischbach MA; Parkhill J; Cole ST
Genome Res; 2008 May; 18(5):729-41. PubMed ID: 18403782
[TBL] [Abstract][Full Text] [Related]
20. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs.
Almeida Da Silva PE; Palomino JC
J Antimicrob Chemother; 2011 Jul; 66(7):1417-30. PubMed ID: 21558086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
